Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma
Chobrutskiy BI, Yeagley M, Tipping P, Zaman S, Diviney A, Patel DN, Falasiri S, Uversky VN, Blanck G. Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma. Oncogene 2019, 39: 1773-1783. PMID: 31740784, DOI: 10.1038/s41388-019-1101-2.Peer-Reviewed Original ResearchMeSH KeywordsComplementarity Determining RegionsGene Expression Regulation, NeoplasticGliomaHumansIsocitrate DehydrogenaseKaplan-Meier EstimateMutationNeoplasm GradingConceptsLow-grade gliomasComplementarity-determining region 3T cell receptor beta chainImmune responseGrade gliomasIDH1 mutantChronic inflammationReceptor beta chainCancer immunologyLGG prognosisNRAS mutantsSurvival rateCancer developmentCDR3 domainsGliomasImmune receptorsBeta chainAnticancer processesSurvival